MedTrace Logo

Study on the Efficacy and Safety of Avatricopal in Patients With CLD Complicated With Thrombocytopenia

NCT06642740 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2024-10-15

No results posted yet for this study

Summary

In this study, patients with chronic liver disease undergoing selective invasive and minimally invasive surgery combined with thrombocytopenia were enrolled. After enrollment, liver disease treatment was supplemented with avatripopal for 5 days. Biochemical indexes of avatripopal were monitored during treatment and after withdrawal. The proportion of patients with platelet count ≥50×10\^9/L on the day of selective invasive and minimally invasive surgery was analyzed. The incidence of adverse events was observed.

Conditions

Interventions

OTHER

Platelet count

divide into two groups based on platelet count

Sponsors & Collaborators

  • Beijing Ditan Hospital

    lead OTHER

Principal Investigators

  • Yao Xie, Doctor · Beijing Ditan Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-06-01
Completion
2025-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06642740 on ClinicalTrials.gov